Want to join the conversation?
$AMGN presented new key data evaluating Kyprolis (carfilzomib) -based regimens in patients with relapsed multiple myeloma. The data showed Kyprolis in combination with dexamethasone extended disease progression compared to bortezomib plus dexamethasone across range of difficult-to-treat populations.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.